Q-Med's Second Gamble
Q-Med is looking to solve two big problems of the disease management business: creating a proprietary hook and selling cost-benefit results to managed care plans which fit within their very short time horizons. The company believes and has evidence that their coronary artery disease monitor can identify patients who will have a heart attack or require some serious medical intervention within the one-to two year time frame of managed care plans.
You may also be interested in...
High-profile experts including Anthony Fauci and Adrian Hill share views at the ICMR symposium on progressing safe COVID-19 vaccines backed by ethical trials executed with appropriate scientific rigor. Human challenge studies, "vaccine nationalism" and equitable access were among the key issues deliberated, while India committed to making its coronavirus vaccines and related capabilities available to the world.
The company has executed $400m worth of deals with smaller governments reflecting a $32-$37 price per dose for the two-shot mRNA-1273 vaccine, but said larger deals will be done at lower prices.
A diclofenac topical analgesic is first, likely followed by a line extension for its Prevacid 24HR PPI brand. Perrigo also plans to introduce natural-based products that “leverage our expertise in Europe."